2 Warren Buffett Stocks to Buy Without Hesitation If You Have $1,000 to Invest Right Now

2025.02.02

Share

The Oracle of Omaha, Warren Buffett, is arguably one of the most famous investors of all time. Many investors have sought to replicate his investing strategy as emphasized by the holdings of Buffett's multinational conglomerate Berkshire Hathaway.

It's important to carefully evaluate any stock you're considering to ensure it's a solid pick for your portfolio, aligns with your risk-tolerance level, and fits with the overall objectives you've set for your holdings. That said, adding businesses favored by respected and successful investors like Warren Buffett can be a great way to boost your returns while growing your basket of stocks with time.

Here are two such Warren Buffett stocks to consider adding to your buy basket right now.

Buffett owns a 44% stake in DaVita (NYSE: DVA) through Berkshire Hathaway, a position that comprises just around 2% of the multinational conglomerate's wide-ranging portfolio. In case you're not familiar with this business, DaVita is a healthcare provider specializing in kidney care services including dialysis and chronic care management.

DaVita's flagship dialysis business serves a wide variety of needs affecting kidney disease patients, including those who need acute hospital care or can receive dialysis at home. As the top provider of home dialysis in the U.S., DaVita has a broad addressable market opportunity based on a durable healthcare need.

It's estimated that approximately 68% of patients in the U.S. with the chronic kidney disease end-stage renal disease require dialysis. That's a patient population of close to 1 million and growing. According to the National Kidney Foundation, over 2 million people worldwide currently receive treatment with dialysis or a kidney transplant to stay alive, with dialysis being the much more common solution.

DaVita operates a network of dialysis centers around the world. The company serves hundreds of thousands of patients a year at its roughly 3,042 outpatient dialysis centers. Less than 400 of those centers are located outside the U.S. DaVita's ability to grow its revenue and profits is heavily tied to the number of dialysis treatments it performs and payer reimbursement rates. The more treatments it facilitates, the more money it makes.

However, the primary source of its revenue and profits are government health insurance programs like Medicare and Medicaid, along with commercial payers covering costs for insureds receiving dialysis. DaVita's business benefits from the fact that it serves a consistent healthcare need that is broadly covered by payers. For example, patients on Medicare have 80% of dialysis treatment costs covered.


background

Stay Ahead with StockBurger!

Real-time meme stock trends powered by social media insights. Be the first to know about new market waves.

hand